Methods | RCT, active‐controlled, open‐label trial Date of study: Feb 2002‐Feb 2005 Location: multicentre (n = 5), Sweden |
|
Participants |
Randomised: 84 participants (mean age: 48 years (methotrexate), 46 years (ciclosporin); 55 male) Inclusion criteria
Dropouts and withdrawals
|
|
Interventions |
Intervention A. Methotrexate + folic acid (n = 41), orally, 7.5 mg/kg /week (5 mg folic acid except days of methotrexate), 12 weeks Control intervention B. Ciclosporin (n = 43), orally, 3 mg/kg, divided into 2 doses, 12 weeks |
|
Outcomes | Assessments at 12 weeks Primary outcomes of the trial
Secondary outcomes of the trial
|
|
Notes | Funding (p121): "Financial support from the Swedish Psoriasis Association and the Welander foundation" Declarations of interest (p116): "none declared" |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Low risk | Quote (p 117): "Randomization was performed with the use of computer‐generated random numbers, numbers by calling a central telephone number" Comment: probably done |
Allocation concealment (selection bias) | Low risk | Quote (p 117): "Randomization was performed with the use of computer‐generated random numbers, numbers by calling a central telephone number" Comment: probably done |
Blinding of participants and personnel (performance bias) All outcomes | High risk | Comment: not blinded |
Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | Quote (p 117): "Blinded assessors performed the PASI at baseline and monthly thereafter" Comment: no description of method used to guarantee no communication between care givers or participants and assessors |
Incomplete outcome data (attrition bias) All outcomes | High risk | Randomly assigned 84, analysed 68 Management of missing data: not ITT analysis |
Selective reporting (reporting bias) | Unclear risk | Comment: no protocol was available. The pre‐specified outcomes mentioned in the methods section appeared to have been reported |